Literature DB >> 11125883

Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection.

M Sester1, U Sester, H Köhler, T Schneider, L Deml, R Wagner, N Mueller-Lantzsch, H W Pees, A Meyerhans.   

Abstract

OBJECTIVES: Upon HIV infection, strong antiviral cytotoxic and helper T cell responses are generated. They are considered to be an important component in the control of HIV viral load. A simple and rapid whole blood assay was established to quantify and simultaneously characterize HIV-reactive CD4 and CD8 cells. The assay was applied to evaluate the effect of antiretroviral therapy on HIV-specific T cell responses.
METHODS: Whole blood of 33 HIV-infected individuals was specifically stimulated by HIV-1 Pr55gag, and activation-induced intracellular cytokine expression in CD4 and CD8 T cells was analysed by flow cytometry.
RESULTS: HIV-1-specific CD8 and CD4 T cells can be quantified simultaneously. As specific antigen, HIV-1 Pr55gag virus-like particles were superior to soluble protein, especially for the activation of CD8 T cells. In untreated individuals, a high frequency of HIV-specific T cells was observed. The frequency of CD8 T cells was consistently higher than the respective CD4 T cell response, thus demonstrating a dominance in CD8 T cell expansion in persistent HIV infection. Patients on antiretroviral therapy showed a significant reduction in HIV-specific CD4 and, even more strikingly, CD8 T cells.
CONCLUSION: The whole blood assay provides a rapid estimate of the total antiviral T cell resources, and is highly suited for a clinical setting. It may thus have widespread applications for the evaluation of vaccination strategies and immunotherapy. Because antiretroviral therapy significantly reduces both HIV-specific cytotoxic and helper T cell responses, future therapeutic strategies should aim at improving cellular antiviral immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11125883     DOI: 10.1097/00002030-200012010-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Glenda Gray; Gayle Sherman; Ashraf Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS Res Hum Retroviruses       Date:  2009-10       Impact factor: 2.205

2.  Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus.

Authors:  Martina Sester; Urban Sester; Barbara Gärtner; Boris Kubuschok; Matthias Girndt; Andreas Meyerhans; Hans Köhler
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus.

Authors:  Matthieu Perreau; Eric J Kremer
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load.

Authors:  Florence Buseyne; Daniel Scott-Algara; Françoise Porrot; Béatrice Corre; Nassima Bellal; Marianne Burgard; Christine Rouzioux; Stéphane Blanche; Yves Rivière
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

6.  Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Gregory B Pott
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

7.  Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Samantha L Donninger; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

8.  Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo.

Authors:  Alexandra Schuetz; Antelmo Haule; Klaus Reither; Njabulo Ngwenyama; Andrea Rachow; Andreas Meyerhans; Leonard Maboko; Richard A Koup; Michael Hoelscher; Christof Geldmacher
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

9.  Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Authors:  Luisa Klotz; Berit Grützke; Maria Eveslage; Michael Deppe; Catharina C Gross; Lucienne Kirstein; Anita Posevitz-Fejfar; Tilman Schneider-Hohendorf; Nicholas Schwab; Sven G Meuth; Heinz Wiendl
Journal:  BMC Neurol       Date:  2015-06-23       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.